US2020115472A1PendingUtilityA1

Pharmaceutical compounds comprising modified fucans and methods relating thereto

70
Assignee: ARC MEDICAL DEVICES INCPriority: Jul 27, 2009Filed: May 17, 2019Published: Apr 16, 2020
Est. expiryJul 27, 2029(~3 yrs left)· nominal 20-yr term from priority
Inventors:Christopher Michael Kevin Springate
A61K 9/06A61K 9/0014A61K 9/08A61P 29/00A61P 7/00A61K 9/0019A61Q 19/005A61P 17/02A61K 31/737A61P 9/10A61K 31/715C08B 37/0006A61P 9/00A61P 17/10A61K 8/73A61P 17/00A61P 31/04A61P 35/00A61P 39/02A61P 41/00A61K 2121/00
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.

Claims

exact text as granted — not AI-modified
1 . A medical composition comprising a therapeutically effective amount of a modified fucan in combination with at least one pharmaceutically acceptable excipient, filler, carrier or diluent, wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of less than about 2% w/w and a protein content of less than about 2% w/w. 
     
     
         2 - 27 . (canceled) 
     
     
         28 . The medical composition of  claim 1  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0 to 10%. 
     
     
         29 . The medical composition of  claim 28  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0.5 to 5%. 
     
     
         31 . The medical composition of  claim 29  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0 to 2%. 
     
     
         32 . The medical composition of  claim 1  wherein the modified fucan has a protein content of between about 0 to 10% w/w. 
     
     
         33 . The medical composition of  claim 32  wherein the modified fucan has a protein content of between about 0 to 5% w/w. 
     
     
         34 . The medical composition of  claim 33  wherein the modified fucan has a protein content of between about 0 to 2% w/w. 
     
     
         35 . The medical composition of  claim 1  wherein the composition is a solution, gel, sol or suspension with a modified fucan concentration of between about 0.001 to 10% w/v. 
     
     
         36 . The medical composition of  claim 35  wherein the modified fucan concentration is about 5% w/v. 
     
     
         37 . The medical composition of  claim 35  wherein the modified fucan concentration is between about 0.001 and 1% w/v. 
     
     
         38 . The medical composition of  claim 37  wherein the modified fucan concentration is about 0.05% w/v. 
     
     
         39 . The medical composition of  claim 38  wherein the modified fucan concentration is about 0.03% w/v. 
     
     
         40 . The medical composition of  claim 1  wherein the modified fucan is prepared from the brown marine algae  Laminaria hyperborean.    
     
     
         41 . The medical composition of  claim 1  wherein the modified fucan is prepared from the brown marine algae  Laminaria japonica.    
     
     
         42 . The medical composition of  claim 1  wherein the modified fucan is prepared from the brown marine algae  Undaria pinnatifida.    
     
     
         43 . A medical composition comprising a therapeutically effective amount of a modified fucan in combination with at least one pharmaceutically acceptable excipient, filler, carrier or diluent, wherein the modified fucan has a sulphate content of between about 14 to 40% w/w; a total carbohydrate content of between about 37 to 75% w/w; a fucose content as a percentage of total carbohydrate content of between about 70 to 100%; an acetyl content as a ratio of acetyl:fucose of between less than about 2% w/w; a protein content of less than about 2% w/w; an appearance of white, off-white, light yellow, light orange, light green or light brown; and when made up to a 0.1% w/v solution results in a solution with a pH of about 4 to 8. 
     
     
         44 . The medical composition of  claim 43  wherein the modified fucan has a fucose content as a percentage of total carbohydrate content of between about 90 to 100%. 
     
     
         45 . The medical composition of  claim 44  wherein the modified fucan has a molecular weight distribution such that the portion from about 0 to 5,000 g/mol comprises between about 0 to 25% w/w, the portion from about 5,000 to 60,000 g/mol comprises between about 0 to 55% w/w, the portion from about 60,000 to 200,000 g/mol comprises between about 5 to 35% w/w, the portion from about 200,000 to 1,600,000 g/mol comprises between about 0 to 50% w/w, and the portion from more than about 1,600,000 g/mol comprises about 0 to 50% w/w %. 
     
     
         46 . The medical composition of  claim 45  wherein the modified fucan has a molecular weight distribution such that the portion from about 0 to 5,000 g/mol comprises between about 0 to 25% w/w, the portion from about 5,000 to 60,000 g/mol comprises between about 5 to 38% w/w, the portion from about 60,000 to 200,000 g/mol comprises between about 10 to 30% w/w, the portion from about 200,000 to 1,600,000 g/mol comprises between about 8 to 43% w/w, and the portion from more than about 1,600,000 g/mol comprises between about 1 to 33% w/w. 
     
     
         47 . The medical composition of  claim 43  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0 to 10%. 
     
     
         48 . The medical composition of  claim 47  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0 to 5%. 
     
     
         49 . The medical composition of  claim 48  wherein the modified fucan has an acetyl content as a ratio of acetyl:fucose of between about 0 to 2%. 
     
     
         50 . The medical composition of  claim 43  wherein the modified fucan has a protein content of between about 0 to 10% w/w. 
     
     
         51 . The medical composition of  claim 43  wherein the modified fucan has a protein content of between about 0 to 5% w/w. 
     
     
         52 . The medical composition of  claim 51  wherein the modified fucan has a protein content of between about 0 to 2% w/w. 
     
     
         53 . The medical composition of  claim 43  wherein the composition is a solution, gel, sol or suspension with a modified fucan concentration of between about 0.001 to 10% w/v. 
     
     
         54 . The medical composition of  claim 53  wherein the modified fucan concentration is about 5% w/v. 
     
     
         55 . The medical composition of  claim 53  wherein the modified fucan concentration is between about 0.001 and 1% w/v. 
     
     
         56 . The medical composition of  claim 55  wherein the modified fucan concentration is about 0.05% w/v. 
     
     
         57 . The medical composition of  claim 56  wherein the modified fucan concentration is about 0.03% w/v. 
     
     
         58 . The medical composition of  claim 43  wherein the modified fucan is prepared from the brown marine algae  Laminaria hyperborean.    
     
     
         59 . The medical composition of  claim 43  wherein the modified fucan is prepared from the brown marine algae  Laminaria japonica.    
     
     
         60 . The medical composition of  claim 43  wherein the modified fucan is prepared from the brown marine algae  Undaria pinnatifida.

Join the waitlist — get patent alerts

Track US2020115472A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.